Outsourced clinical investigation: legal aspects

Last Wednesday 13 April I spoke at Informa’s 6th Annual Clinical Evaluations and Investigations for Medical Devices conference about legal aspects of outsourced clinical investigation in the medical devices industry.

Proceeding from showing that the CRO, the site, the investigators and the manufacturer have potentially differing interests that the agreement must align the presentation describes how to deal with business compliance issues (anti-kickback and fraud regulation) and regulatory issues. Especially business compliance issues become more and more important because such issues coming up later may not only lead to government action against a company resulting in fines, but may also lead to invalidation of the clinical studies affected if the investigators turn out to have been improperly influenced, and is something that you will not find in ISO 14155, the standard for medical devices clinical trials.

The presentation furthermore gave a detailed roadmap of an agreement for outsourced clinical investigation and a number of drafting tips per clause of the agreement roadmap. Some mechanisms were clarified in more detail, both from CRO and manufacturer perspective such as IP, milestones, termination regime and choice of law and forum.

Finally, I hope to have shown how vitally important it is for a good clinical investigation outsourcing agreement that the regulatory affairs staff and the lawyers concerned approach it as a joint project so the best results are achieved because nothing is overlooked, rather than review the agreement one after the other and assume the other department.


Navigate through our knowledgebase

Related articles

Article

Bottleneck of bottlenecks for notified body capacity

People that are downplaying the notified body bottleneck may need to start to revisit their position with notified body LRQA now also dropping out of the notified body pool for medical devices…

Read more

Article

Vanilla custard or custard with vanilla taste?

In a recent decision of the Board of Appeal of the Dutch Advertising Code Committee (ACC), it was made clear that providing food information to consumers is serious business. The ACC in the Netherlands is a self-regulatory body, comparable to the Advertising Standards Authority in the UK and the German Advertising Standards Council (“Deutscher Werberat”)  […]

Article

Trends at Vitafoods … and what you should know if you decide to be part of it

From 7 – 9 May 2019, the Vitafoods conference took place again in Geneva. For a few years in a row, I presented at the Education Program. This year I was asked to discuss the application of CBD in food products, which is currently a hot topic. Below, I will share the insight from my […]